Siolta Therapeutics
- Headquarters
- San Francisco Bay Area, California
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- sioltatherapeutics.com
- Total Funding
- $88.5M
- Last Round
- $12.0M Series CMar 2024
About
Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutic products (LBPs) targeting inflammatory and allergic diseases through manipulation of the human microbiome. Their proprietary Precision Symbiotics Platform designs multi-strain microbial consortia to prevent conditions such as atopic dermatitis and food allergy in newborns. Founded as a UCSF spinout, their lead program STMC-103H has received FDA Fast Track Designation.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account